Mixtard 30

Maa: Armenia

Kieli: englanti

Lähde: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Aktiivinen ainesosa:

insulin human (recombinant DNA)

Saatavilla:

Novo Nordisk A/S

INN (Kansainvälinen yleisnimi):

insulin human (recombinant DNA)

Annos:

100IU/ml

Lääkemuoto:

suspension for injection

Prescription tyyppi:

Prescription

Pakkausseloste

8-0191-00-096-1
Regulatory Operations
Insert: 2010-125x295-001
Current 1.0
I10 vial
Professionel
COLOUR: PMS 280C
100 IU/ml
MIXTARD® 30
Suspension for injection in vial.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Insulin human, rDNA (produced by recombinant DNA
technology in_ Saccharomyces cerevisiae_).
1 ml contains 100 IU of insulin human.
1 vial contains 10 ml equivalent to 1,000 IU.
One IU (International Unit) corresponds to 0.035 mg of
anhydrous human insulin.
Mixtard® is a mixture of dissolved insulin and isophane
(NPH) insulin.
Mixtard® 30 consists of 30% dissolved insulin and
70% isophane insulin.
PHARMACEUTICAL FORM
Suspension for injection in vial.
Cloudy, white, aqueous suspension.
THERAPEUTIC INDICATIONS
Treatment of diabetes mellitus.
POSOLOGY AND METHOD OF ADMINISTRATION
Mixtard® is a dual-acting insulin. It is a biphasic
formulation containing both fast-acting and long-acting
insulin. Premixed insulin products are usually given once
or twice daily when a rapid initial effect together with a
more prolonged effect is desired.
DOSAGE
Dosage is individual and determined in accordance with
the needs of the patient. The individual insulin
requirement is usually between 0.3 and 1.0 IU/kg/day. The
daily insulin requirement may be higher in patients with
insulin resistance (e.g. during puberty or due to obesity)
and lower in patients with residual, endogenous insulin
production.
An injection should be followed within 30 minutes by
a meal or snack containing carbohydrates.
DOSAGE ADJUSTMENT
Concomitant illness, especially infections and feverish
conditions, usually increases the patient’s insulin
requirement. Concomitant diseases in the kidney, liver or
affecting the adrenal, pituitary or thyroid gland can
require changes in the insulin dose. Adjustment of dosage
may also be necessary if patients change physical activity
or their usual diet. Dosage adjustment may be necessary
when transferring patients from one insulin preparation to
another.
ADMINISTRATION
For subcutaneous use. Insulin suspensions are n